Viriom Became a Member of "Skolkovo" Innovation Center

Viriom Ltd., member of ChemRar High-Tech Center, received the status of a member of "Skolkovo" innovation center and entered the biomedical technology cluster with its project to develop an effective and safe drug VM-1500 for the treatment of HIV/AIDS.

As part of the project, the company has completed a program of pre-clinical and clinical phase I studies in healthy volunteers in Russia, proving the high safety profile of VM-1500, and also conducted international clinical phase II study in Thailand, where its safety, tolerability and antiviral activity in HIV-positive patients was studied.

The results of this study indicate the superiority of VM-1500 antiviral profile as compared to existing drugs in the class of non-nucleoside reverse transcriptase inhibitors, widely used for HIV therapy. These clinical studies were recently presented at the International Conference on Retroviruses and Opportunistic Infections in Boston (CROI 2014) and were acknowledged by the experts and market analysts.

Currently, Viriom is launching an international, multi-center study of the efficacy and safety of the VM-1500 drug in various doses in HIV-infected patients who have not received prior treatment.

Acquired Immune Deficiency Syndrome (AIDS) - a range of symptoms and infections, the common cause of which is the damage to the immune system. It is caused by human immunodeficiency virus (HIV). Without treatment, HIV infection develops into AIDS in 9-10 years on average. According to the Federal Research Center for AIDS Prevention and Control, the total number of Russians infected with HIV, who were officially registered in the Russian Federation until December 31, 2012, is over 700 thousand people. A critical situation developed among young men, aged 30-34, with 2.4% officially registered as HIV-infected. Among women aged 25-37 years, 1.2% were living with a diagnosis (HIV). Although since the mid 90-ies of the last century highly active antiretroviral therapy was used relatively successfully, serious problems with the treatment of the disease persist until these days. Today doctors have 15 drugs (generally underperforming and very expensive) at their disposal that can extend the life of an AIDS patient. Unfortunately, even the current methods of treatment are available only to 125 thousand patients - 17.8% of the total number of Russian patients.

The emergence of an effective and affordable domestic product of a new generation based on the VM-1500 on the Russian pharmaceutical market will certainly help to reduce the cost of treatment, enabling all patients to receive therapy.

Under a licensing agreement between the companies Viriom and F. Hoffmann La Roche and additions to it, Viriom has the right to sell the drug in the territory of any country in the world. Moreover, VM-1500 can be introduced onto the markets of these territories by Viriom itself or by its partner-distributor, upon consulting with F. Hoffman-La Roche. The priority countries for distribution of the drug include Russia, Belarus, Kazakhstan and Ukraine.

The project is supported by the Ministry of Industry and Trade within the framework of the Federal Program "Development of the pharmaceutical and medical industry of the Russian Federation for the period until 2020 and beyond."